Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis - Takeaways - MDSpire

Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis

  • By

  • Guan-Jiang Huang

  • Zi-Qing Chen

  • Chao-Qing Long

  • Qi-Ping Luo

  • Zhi-Jun Fan

  • Biao-Qing Lu

  • June 16, 2026

  • 0 min

Share

  • 1

    Chronic rhinosinusitis (CRS) affects approximately 11% of adults globally and is characterized by persistent inflammation of the nasal cavity and sinuses.

  • 2

    Microbial metabolites, rather than microbial identity, are emerging as key immunological mediators in the crosstalk between commensal microbiota and host.

  • 3

    Short-chain fatty acids, tryptophan-derived indoles, and secondary bile acids are identified as protective metabolites that modulate immune responses in CRS.

  • 4

    Pathobiont-derived virulence factors, particularly from Staphylococcus aureus, disrupt nasal mucosal immune tolerance and contribute to CRS pathology.

  • 5

    Postbiotic supplementation of purified bioactive metabolites is proposed as a precision therapeutic strategy to restore nasal mucosal immune homeostasis.

Original Source(s)

Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis

  • by Guan-Jiang Huang, Zi-Qing Chen, Chao-Qing Long, Qi-Ping Luo, Zhi-Jun Fan, Biao-Qing Lu

  • June 16, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.